Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for QRX003 to treat Peeling Skin Syndrome (PSS), a rare disease with no current treatment. Supported by positive preliminary clinical data, the company plans to initiate a Phase 2 trial in the second half of 2026. QRX003 is also in development for Netherton…